ORLANDO, FL — May 23, 2002 —
Adding the HER2 antagonist trastuzumab to a neoadjuvant treatment regimen with docetaxel and cisplatin results in node-free presurgery status for more than half of women with advanced or inflammatory breast cancer.
“This regimen proved to be highly active, yielding an unusually high rate of tumor disappearance, which hopefully will translate to an improvement in survival,” said Dr. Judith Hurley, MD, assistant professor of medicine, University of Miami, and consultant, Taylor Breast Health Center, Jackson Memorial Hospital, Miami, Florida.
The largest of the tumors was eight centimeters in diameter. She presented the results here Tuesday at the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO), Dr. Hurley and colleagues enrolled 34 women with locally advanced breast cancer who over-expressed HER2.
They were treated with 4 mg/kg of trastuzumab intravenously on the first day of the regimen, and then were given the drug in a dose of 2 mg/kg intravenously weekly for 11 more cycles. The women received 70 mg/m² of docetaxel and 70 mg/m² of cisplatin on the first day of treatment, at 21-day intervals for a total of four cycles. Granulocyte colony stimulating factor (G-CSF) was administered on the second day of treatment and then on days 24, 44, and 65; epoetin alfa was administered once a week for 12 weeks. The women also were treated with radiation and tamoxifen.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!